Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME

IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics' proprietary CD8aß co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8

Related Keywords

Germany ,Houston ,Texas ,United States ,Twitterand Linkedin ,Eva Mulder ,Cedrik Britten ,Anja Heuer ,Immatic Actengine ,Texasand Tuebingen ,Instagram ,Corporate Communications ,Trophic Communications ,Chief Medical Officer ,All Immatic ,Stem Cell Therapeutics Research Laboratory ,Adoptive Cell Therapies ,Looking Statements ,Investor Relations ,Immatics ,Nnounces ,First ,Dancer ,Patient ,Reated ,Second ,Generation ,Actengine ,Candidate ,Ma203cd8 ,Targeting ,Frame ,